Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed/Cisplatin vs Pemetrexed in EGFR-mutant NSCLC post-TKI
NCT03050437Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Mar 2013
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cisplatin in non-small cell lung cancer (NSCLC), sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
cisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03050437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03050437.